Astrazeneca (AZN) Receivables (2009 - 2026)
Astrazeneca (AZN) posted quarterly Receivables of $14.3 billion for Q2 2026, up 1.14% year-over-year from $14.2 billion in Q2 2025, and up 1.59% quarter-over-quarter from $14.1 billion in Q1 2026.
Astrazeneca (AZN) Receivables (2009 - 2026) Analysis & Trends
Astrazeneca's Receivables history runs 18 years deep, the most recent figure standing at $14.3 billion for Q2 2026.
- In Q2 2026, Receivables rose 1.14% year-over-year to $14.3 billion; the TTM figure through Jun 2026 stood at $14.3 billion (up 1.14% YoY), while the FY2025 annual figure was $15.2 billion, up 17.0% from the prior year.
- Receivables for Q2 2026 stood at $14.3 billion, up from $14.1 billion in the prior quarter.
- The five-year high for Receivables was $15.2 billion in Q4 2025, with the low at $8.7 billion in Q1 2022.
- The 5-year median for Receivables is $11.6 billion (2023), against an average of $11.9 billion.
- The sharpest annual moves came in 2022 and 2024: Receivables soared 74.97% in 2022, then slipped 0.41% in 2024.
- Astrazeneca's Receivables stood at $10.5 billion in 2022, then climbed by 15.26% to $12.1 billion in 2023, then climbed by 6.98% to $13.0 billion in 2024, then rose by 17.0% to $15.2 billion in 2025, then retreated by 5.58% to $14.3 billion in 2026.
- Business Quant data shows AZN's Receivables at $14.3 billion in Q2 2026, $14.1 billion in Q1 2026, and $15.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.87 Bn | 633.12 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 470.41 Bn | 463.84 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 303.87 Bn | 296.18 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 257.75 Bn | 252.85 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 236.40 Bn | 222.41 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 182.11 Bn | 178.93 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 159.54 Bn | 147.84 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 106.30 Bn | 102.13 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn | 10.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.33 Bn |
| Mar 31, 2026 | 14.11 Bn |
| Dec 31, 2025 | 15.18 Bn |
| Sep 30, 2025 | 14.34 Bn |
| Jun 30, 2025 | 14.17 Bn |
| Mar 31, 2025 | 13.25 Bn |
| Dec 31, 2024 | 12.97 Bn |
| Sep 30, 2024 | 11.88 Bn |
| Jun 30, 2024 | 11.05 Bn |
| Mar 31, 2024 | 11.07 Bn |
| Dec 31, 2023 | 12.13 Bn |
| Sep 30, 2023 | 11.30 Bn |
| Jun 30, 2023 | 11.09 Bn |
| Mar 31, 2023 | 10.29 Bn |
| Dec 31, 2022 | 10.52 Bn |
| Sep 30, 2022 | 9.34 Bn |
| Jun 30, 2022 | 8.91 Bn |
| Mar 31, 2022 | 8.68 Bn |
| Dec 31, 2021 | 9.64 Bn |
| Sep 30, 2021 | 8.26 Bn |